Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b
CH Polman, Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Krzysztof Selmaj(University of Warmia and Mazury in Olsztyn), Ludwig Kappos(Novartis (Switzerland)), Christoph Pohl, Frederik Barkhof(Netherlands Institute for Neuroscience), Rupert Sandbrink(Io Therapeutics (United States)), S. Dahms(Bayer (Germany)), David H. Miller(National Hospital for Neurology and Neurosurgery), Mark S. Freedman, H-P Hartung(Heinrich Heine University Düsseldorf), Gilles Edan, Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam), Lars Bauer(UCB Pharma (Germany))
Cited by 75
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k